SCHEMBL6806843

SCHEMBL6806843

CCOC(=O)[C@H](Cc1ncc(-c2ccc(F)cc2)o1)NC(=O)OCc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 1/20 0.43
ATM Q13315 1/20 0.43
NPPA P01160 2/20 0.43
MME P08473 2/20 0.43
TACR1 P25103 1/20 0.43
FAAH O00519 1/20 0.43
TYR P14679 1/20 0.42
CTSL P07711 3/20 0.41
CTSB P07858 2/20 0.41
CTSS P25774 2/20 0.41
CTSK P43235 2/20 0.41
GPR34 Q9UPC5 1/20 0.41
ELANE P08246 1/20 0.41
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
RXRG P48443 1/20 0.40
ALDH1A1 P00352 1/20 0.40
ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6508639 0.94 ATM (0.47) ATMNPPAMMETACR1TYR
SCHEMBL6807187 0.91 PPARA (0.48) ATMNPPAMMETACR1CTSL
SCHEMBL30306923 0.91 ATM (0.43) ATMNPPAMMETACR1TYR
SCHEMBL6254719 0.84 NPPA (0.52) ATMNPPAMMETACR1CTSL
SCHEMBL6807219 0.83 SYK (0.47) ATMNPPAMMETACR1CTSL
SCHEMBL28969031 0.81 NPPA (0.47) ATMNPPAMMETACR1CTSL
SCHEMBL28968928 0.81 NPPA (0.47) ATMNPPAMMETACR1CTSL
SCHEMBL6259306 0.81 PPARA (0.47) TACR1CTSLCTSBCTSSCTSK
SCHEMBL6803500 0.77 TACR1 (0.61) ATMTACR1CTSLCTSBCTSS
SCHEMBL6257672 0.77 ATM (0.46) ATMNPPAMMETACR1CTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040138274-A1 Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders DACK KEVIN NEIL (GB) 2004-07-15 US disclosed
WO-2004056787-A1 CYCLOPENTYL GLUTARAMIDES AND THEIR USE AS NEUTRAL ENDOPEPTIDASE INHIBITORS PFIZER LIMITED (GB) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138274-A1 Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders MME, ECE1, ECE2 MGLL 158/4885ATM 4873/4885NPPA 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.